You are viewing: India Leukapheresis Market analysis
Part of: Leukapheresis Market (Global)

The India Leukapheresis Market was valued at $0.99 Million in 2026 and projected to reach to $1.59 Million by 2031, representing a compound annual growth rate of CAGR 10.1%. India's leukapheresis market is poised for sustained expansion over the forecast period, driven by rising healthcare expenditure and growing prevalence of hematologic malignancies.

India Leukapheresis Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

India Leukapheresis Market Trends and Insights

  • This expansion reflects India's increasing adoption of advanced cell separation technologies and growing demand for therapeutic apheresis procedures.
  • India's healthcare infrastructure improvements and rising prevalence of hematologic malignancies are driving market penetration across major metropolitan centers and emerging tier-2 cities. The leukapheresis market in India is supported by expanding clinical applications in leukemia and lymphoma treatment protocols.
  • India's growing patient population and improving access to specialized oncology centers are accelerating procedure volumes.
  • The 10.1% compound annual growth rate underscores India's position as a high-growth market within the Asia Pacific region, driven by both public and private healthcare sector investments in apheresis technology..

Key Market Statistics

  • CAGR (2026-2031) CAGR 10.1%
  • Market Size, 2026 ~USD 0.99 Million
  • Forecast, 2031 ~USD 1.59 Million
  • Country India

India Leukapheresis Market Overview

Market Valuation Growth :

India's leukapheresis market is valued at USD 0.99 million in 2026 and is projected to reach USD 1.59 million by 2031, representing a robust CAGR of 10.1%, outpacing the global growth rate of 8.9%.

Healthcare Infrastructure Expansion :

Significant improvements in India's healthcare infrastructure, particularly in tier-1 and tier-2 cities, are enabling wider adoption of advanced cell separation technologies and therapeutic apheresis procedures.

Rising Hematologic Malignancy Prevalence :

Increasing incidence of blood cancers and hematologic disorders in India is driving demand for leukapheresis procedures, supported by growing awareness and improved diagnostic capabilities across the country.

Technology Adoption Acceleration :

Indian hospitals and diagnostic centers are increasingly investing in automated leukapheresis equipment, driven by the need for efficient patient management and improved clinical outcomes in oncology and hematology departments.

India Leukapheresis Market Dynamics

  • The country's improving medical infrastructure and increasing availability of advanced apheresis technologies in major metropolitan areas are key growth catalysts.
  • Additionally, government initiatives promoting cancer care and diagnostic services are expected to further accelerate market penetration. The market will benefit from growing patient awareness, expanding hospital networks, and rising adoption of therapeutic apheresis in both urban and emerging healthcare centers.
  • However, cost constraints and limited accessibility in rural regions may moderate growth.
  • Strategic partnerships between international manufacturers and Indian healthcare providers are likely to enhance market accessibility and drive innovation in cell separation technologies..

Related Ecosystem

Key Takeaways

  • India's leukapheresis market is valued at USD 0.99 million in 2026 and will reach USD 1.59 million by 2031, representing a 10.1% CAGR.
  • India's expanding oncology infrastructure and rising hematologic malignancy prevalence are primary growth catalysts for leukapheresis adoption.
  • India's market growth outpaces the global average, positioning the country as a high-priority market for apheresis technology providers.
  • India's public and private healthcare sector investments are accelerating leukapheresis procedure accessibility across urban and emerging markets.

Leukapheresis Market Report Scope

Report Metric Details
Base Year 2026
Fastest Growing Segment MULTIPLE MYELOMA (Indication)
Forecast Period 2026–2031
Growth Rate CAGR of 8.9% from 2026 to 2031
Largest Segment ACUTE LYMPHOCYTIC LEUKEMIA (Indication)
Market Size Base Year (Billions) ~USD 0.09 (2026)
Revenue Forecast (Billions) ~USD 0.14 (2031)
Segments Covered Product Type, Product Type 2024–2031, Type, Application, End User, Indication, Leukopak Type

India Leukapheresis Market Report Segmentation

7 segment dimensions are covered across the global market.

By Product Type

  • Devices
  • Disposables
  • Leukapheresis Devices
  • Leukapheresis Disposables

By Product Type 2024–2031

  • Collection Kits & Accessories
  • Filters & Membrane Consumables
  • Tubing Sets & Collection Bag

By Type

  • Australia
  • Belgium
  • Brazil
  • Canada
  • Centrifugal Devices
  • China
  • Diseased Leukopaks
  • France
  • Germany
  • India
  • Isolated Pbmcs
  • Italy
  • Japan
  • Kingdom Of Saudi Arabia (Ksa)
  • Membrane Separators
  • Mexico
  • Mobilized Leukopaks
  • Netherlands
  • New Zealand
  • Non-Mobilized Leukopaks
  • Poland
  • Rest Of Asia Pacific
  • Rest Of Europe
  • Rest Of GCC Countries
  • Rest Of Latin America
  • Rest Of Middle East & Africa
  • South Korea
  • Spain
  • Switzerland
  • Thailand
  • UK
  • United Arab Emirates (UAE)
  • US

By Application

  • Research Applications
  • Therapeutic Applications

By End User

  • Academic & Research Institutes
  • Blood Component Providers & Blood Centers
  • Contract Research Organizations
  • Hospitals & Transfusion Centers
  • Pharmaceutical & Biotechnology Companies

By Indication

  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia
  • Hepatocellular Carcinoma
  • Multiple Myeloma
  • Non-Hodgkin’S Lymphoma
  • Other Indications
  • Pancreatic Cancer

By Leukopak Type

  • Diseased Leukopaks
  • Isolated Pbmcs
  • Mobilized Leukopaks
  • Non-Mobilized Leukopaks

INDIA: LEUKOPAKS MARKET, BY END USER, 2024–2031

Segment20242025202620272028202920302031CAGR (%)
ACADEMIC & RESEARCH INSTITUTES4.595.235.976.847.849.0210.3911.9915
CONTRACT RESEARCH ORGANIZATIONS0.440.490.550.610.690.770.870.9812.4
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES1.641.92.22.562.983.484.064.7616.6
TOTAL6.677.628.7310.0111.5113.2715.3217.7415.2

INDIA: LEUKAPHERESIS MARKET, BY END USER, 2024–2031

Segment20242025202620272028202920302031CAGR (%)
ACADEMIC & RESEARCH INSTITUTES0.150.160.170.190.210.230.250.289.7
BLOOD COMPONENT PROVIDERS & BLOOD CENTERS0.480.530.590.660.730.810.911.0111.2
HOSPITALS & TRANSFUSION CENTERS0.30.330.360.40.440.490.540.610.6
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES0.090.10.10.110.120.130.150.168.5
TOTAL1.011.121.231.361.51.671.842.0410.6

Target Audience

  • Medical Device Manufacturers : Manufacturers of leukapheresis and apheresis equipment need India-specific market data to assess market potential, plan product localization strategies, and identify distribution partnerships in this high-growth emerging market.
  • Healthcare Investors & PE Firms : Investment professionals require detailed India market analysis to evaluate opportunities in healthcare infrastructure, diagnostic centers, and oncology services, with quantified growth projections and market dynamics.
  • Hospital & Diagnostic Center Operators : Healthcare facility operators need market insights to justify capital investments in leukapheresis equipment, understand competitive positioning, and plan service expansion in oncology and hematology departments.
  • Pharmaceutical & Biotech Companies : Companies developing cell therapies and cancer treatments require India market data to understand apheresis service availability, treatment adoption rates, and patient population dynamics for clinical trial planning.
  • Healthcare Consultants & Analysts : Consulting firms and research analysts need comprehensive India market data to support client advisory work, competitive benchmarking, and strategic recommendations in the medical device and healthcare services sectors.

Key Companies in the India Leukapheresis Market

CompanyHQOwnershipStrongest segments
MAXCYTE, INCUnited StatesPublic CompanyExPERT instruments (ATx, STx, GTx, VLx),Disposable processing assemblies (PAs) and consumables,Licensing and technology access fees,

MAXCYTE, INC

MaxCyte, Inc. is a United States-based biotechnology company founded in 1998 that specializes in cell engineering technologies. As a publicly traded company, MaxCyte operates with 91 employees and develops innovative solutions for cell-based therapies and research applications.

Reasons to Buy this Report

  • India-Specific Market Sizing : Access precise valuation data for India's leukapheresis market with verified 2026 baseline (USD 0.99M) and 2031 forecast (USD 1.59M), enabling accurate business planning and investment decisions tailored to the Indian market.
  • Competitive Growth Intelligence : Understand India's 10.1% CAGR outperformance versus global 8.9% growth, identifying India as a high-priority market for expansion, product launches, and strategic resource allocation in the apheresis sector.
  • Healthcare Infrastructure Insights : Gain detailed understanding of India's improving healthcare infrastructure, hospital network expansion, and technology adoption patterns to identify optimal market entry points and partnership opportunities.
  • Disease Prevalence & Demand Drivers : Access comprehensive analysis of rising hematologic malignancy prevalence in India, patient demographics, and treatment demand patterns to inform product development and marketing strategies for the Indian market.
  • Regional Market Segmentation : Leverage India-specific segmentation by geography, hospital type, and end-user segments to identify high-growth pockets, underserved regions, and opportunities for targeted market penetration and revenue optimization.

Frequently asked questions

What is the current market size of leukapheresis in India?

India's leukapheresis market was valued at USD 0.99 million in 2026 and is expected to grow to USD 1.59 million by 2031.

What is the projected growth rate for India's leukapheresis market?

India's leukapheresis market is projected to grow at a compound annual growth rate (CAGR) of 10.1% from 2026 to 2031.

What factors are driving leukapheresis market growth in India?

Key drivers include India's improving healthcare infrastructure, rising prevalence of hematologic malignancies, expanding oncology centers, and increased adoption of advanced apheresis technologies.

How does India's leukapheresis market compare to global trends?

India's 10.1% CAGR exceeds the global average of 8.9%, making India one of the fastest-growing leukapheresis markets in the Asia Pacific region.

Which healthcare sectors are contributing to leukapheresis growth in India?

Both public and private healthcare sectors in India are investing in apheresis technology, with major contributions from specialized oncology centers in metropolitan and tier-2 cities.

RESEARCH METHODOLOGY

This study extensively used both primary and secondary sources. The research involved studying various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the usage of comprehensive secondary sources, directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the leukapheresis market. It was also used to identify key players in the market and classify and segment the industry based on trends to the most detailed level. Additionally, significant developments related to market and technology perspectives were noted. A database of the primary industry leaders was also created using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the leukapheresis market. Primary sources from the demand side include healthcare professionals from blood component providers & blood centers, academic & research institutes, pharmaceutical & biotechnology companies, and hospitals & transfusion centers.

A breakdown of the primary respondents is provided below:

BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS, BY COMPANY TYPE, DESIGNATION, AND REGION

Leukapheresis Market
Size, and Share

Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.

Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the leukapheresis market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

Leukapheresis Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Market Definition

Leukapheresis is the process of separating white blood cells from the whole blood. Therapeutic leukapheresis procedures are used to treat hyperleukocytic leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin’s lymphoma.

Leukopaks are enriched leukapheresis products that contain mononuclear leukocytes (lymphocytes and monocytes) and are used to develop cell-based therapeutics

Key Stakeholders

  • Apheresis device manufacturers and distributors
  • Leukapheresis product manufacturers and distributors
  • Leukopak manufacturers and distributors
  • Pharmaceutical and biotechnology companies
  • Healthcare service providers (including hospitals and transfusion centers)
  • Cancer treatment centers
  • Blood component providers & blood centers
  • Contract research organizations (CROS)
  • Academic and research institutes
  • Government associations
  • Market research and consulting firms
  • Venture capitalists and investors

Report Objectives

  • To define, describe, segment, and forecast the leukapheresis market by type, application, end user, and region, and the leukopaks market, by type, indication, end user, and region
  • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall leukapheresis market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the leukapheresis market in five main regions (along with their respective key countries), namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players in the leukapheresis market and comprehensively analyze their core competencies and market share
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships

Available customizations:

With the given market data, MarketsandMarkets offers customizations to meet your company’s specific needs. The following customization options are available for the report:
  • Company Information

Detailed analysis and profiling of additional market players (up to 5)

  • Geographic Analysis

Further breakdown of the Rest of Europe leukapheresis market into Austria, Finland, and other countries

Further breakdown of the Rest of Latin America leukapheresis market into Colombia, Chile, and other countries

  • Competitive Landscape Assessment

Market share analysis for North America and Europe, which provides market shares of the top 3–5 key players in the leukapheresis market

Competitive leadership mapping for established players in the US

 

Get the Full Leukapheresis Market Report

Full forecast, segment splits, and company analysis for all Leukapheresis Market.

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
DMCA.com Protection Status